Chief
Division of Breast Oncology
Dana-Farber Cancer Institute;
Associate Professor
Harvard Medical School
Boston, Massachusetts
For pioneering work dedicated to optimizing targeted therapies for HER2-positive breast cancer through innovative clinical trials. Specifically, Dr. Tolaney’s APT trial demonstrated the efficacy of a less intensive regimen involving paclitaxel and trastuzumab for early-stage, node-negative disease, effectively transforming national and international clinical treatment guidelines. Her leadership in establishing biomarker-driven personalized therapy approaches for cancer, including the development of CDK4/6 inhibitors has significantly advanced care in both metastatic and adjuvant settings, shaping the future of precision oncology for breast cancer patients.
The AACR Award for Outstanding Investigator for Breast Cancer Research was established by the AACR to recognize an early-career investigator for meritorious achievements in basic cancer research. The award is intended to recognize an individual who has not yet reached 46 years of age at the time of their award presentation. To learn more, please visit the press release.
View Past Recipients.